Senolytics: ABT-737

Another senolytic was recently discovered ABT-737 which also targets the BCL family and has shown promising results, in this study they also tested Venetoclax and concluded it has additive effects when used with drugs that target two other major BCL pathways (BCL-W and BCL-XL) which they identify as the primary pathways that control resistance to cell death in senescent cells. It would therefore make sense to combine additive drugs like Venetoclax with drugs such as Dasatinib or ABT-737 to potentially increase the efficacy of Senolytic therapy.